Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (11931)	6/6/2004 7:54:35 AM
From: zeta1961	Read Replies (3) \| Respond to of 52153

>>>>>>>TELK<<<<< Peter et. al....these results although presented in a general poster session, were very well received from their peers, and analysts despite the small cohort size...their CR patients remains in CR...same with PR patients....and some stable disease pts trending toward PR at this point... There is a 100 patientish gemcitabine/oxaliplatin study which will have better #'s but the patient population is not heavily pretreated like TELK's Overall it's a jubilant atmosphere down here about the novels...although the Tarceva P3 lung disappointing to onc's ...showing 2 month advantage...but they've got some presentations using it concomitantly with other agents... Seems like some PR's flowing before papers are even presented...good to see Telk didn't do that... I can say that erbitux P3 study is so complicated...I will be attending that session to see how they plan on making sense of the results... here's a link to the trial design...thoughts? clinicaltrials.gov Will update as I can...gotta' dash for an 8am session... Rick, the immunotherapy session is quite interesting...I have a couple of presentations during it but will try my best...I too am quite eager to listen in... I have RSR comments to post another time... Regards, Zeta